J&J's Spravato Shows Sustained Antidepressant Effects Six Months After Treatment Discontinuation in Real-World Study
核心洞察
Johnson & Johnson's ECHO study demonstrates that Spravato (esketamine nasal spray) maintains antidepressant effects for six months after patients discontinue treatment, with most patients showing no signs of relapse.
The Phase IV real-world study of 570 patients with severe treatment-resistant depression showed significant MADRS score improvements of 14.4 points at 12 weeks and 17.6 points at 48 weeks of treatment.
The study represents the largest European real-world dataset for esketamine and provides the first evidence of treatment durability after discontinuation in clinical practice settings.
Johnson & Johnson announced compelling new data from its Phase IV ECHO study demonstrating that Spravato (esketamine nasal spray) maintains antidepressant effects for six months after patients discontinue treatment. The findings, presented at the 2026 European Psychiatric Association Congress in Prague, represent the first real-world evidence of sustained treatment durability for esketamine in treatment-resistant depression (TRD).
Robust Real-World Effectiveness Confirmed
The ECHO study enrolled 570 patients across Europe and Israel with severe, chronic TRD characterized by a mean Montgomery-Åsberg Depression Rating Scale (MADRS) score of 33.3 and episodes lasting three years or longer. Of these patients, 301 continued into the six-month post-treatment follow-up period.
Treatment with esketamine nasal spray resulted in statistically significant improvements in depressive symptoms, with mean MADRS score reductions of 10.3 points at week 4 (95% CI: -11.1, -9.5; p<0.001), 14.4 points at week 12 (95% CI: -15.4, -13.5; p<0.001), and 17.6 points at week 48 (95% CI: -19.4, -15.8; p<0.001).
"These results reinforce esketamine nasal spray as an effective option for adults with treatment resistant depression, many of whom have spent too long cycling through treatments that don't meaningfully improve their symptoms," said Dr. Christine Reif-Leonhard from the University Hospital Frankfurt.
Unprecedented Durability Data
The study's most significant finding was the maintenance of treatment benefits after discontinuation. Patients who stopped taking Spravato showed a mean change of only -1.4 points from post-treatment follow-up baseline to week 24, indicating sustained symptom stability with no indication of relapse.
"The ECHO study is unique in that, for the first time, we have evaluated the durability of effect in real world practice after stopping esketamine nasal spray treatment in patients with treatment resistant depression," said Tamara Werner-Kiechle, J&J's head of neuroscience for EMEA. "Creating respite from severe depressive symptoms that lasts beyond the immediate treatment period will significantly improve the lives of people affected by this devastating disease."
Complex Patient Population
The real-world patient cohort presented significant clinical complexity, with high treatment resistance reflected by a mean of 3.8 prior treatment failures in the current episode. Additionally, 45.6% of patients had substantial psychiatric comorbidities, and approximately 47% were not working, underlining the severity of illness and real-world implications.
The mean treatment duration was approximately nine months, with esketamine 84 mg being the highest dose taken in 79.3% of patients and the most frequently administered dose in 67.4% of patients.
Safety Profile Consistent
The safety profile remained consistent with previous studies, with no new safety signals identified. Treatment-emergent adverse events occurred in 81.4% of patients, leading to treatment discontinuation in 7.7% of cases. The most commonly reported adverse events were dissociation (35.1%), dizziness (33.5%), and increased blood pressure (21.4%).
Addressing Unmet Medical Need
The results come as depression is predicted to become the leading cause of global disease burden by 2030, according to the World Health Organization. Werner-Kiechle emphasized that approximately one-third of people with major depressive disorder don't adequately respond to available antidepressants, with TRD representing an area of significant unmet need.
Currently, Spravato is the only monotherapy approved for TRD, making these durability findings particularly significant for treatment planning and patient outcomes.
Implications for Psychedelic Medicine Development
According to GlobalData (搜索) analyst Philippa Salter, Spravato's success may facilitate the uptake of other psychedelic therapies in development. "Since Spravato is only available through a restricted programme, it is likely that future psychedelic therapies approved for TRD will also follow this pathway," Salter noted.
The infrastructure and processes established for Spravato administration could benefit companies developing psychedelic drugs like AtaiBeckley (搜索)'s mebufotenin benzoate (搜索) nasal spray and Compass Therapeutics' COMP360. However, Salter cautioned that longer monitoring requirements for new psychedelics could increase market entry hurdles, as Spravato already requires two hours of post-administration monitoring.
GlobalData (搜索) forecasts that Spravato will generate $4.9 billion in revenue by 2032, reflecting its growing importance in the TRD treatment landscape.